Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H20N4O3S |
Molecular Weight | 348.42 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC2=CC(C)=CC=C2
InChI
InChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
Molecular Formula | C16H20N4O3S |
Molecular Weight | 348.42 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00214Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00214
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21190426 |
1.0 µM [IC50] | ||
Target ID: CHEMBL2722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26047574 |
|||
Target ID: GO:0001998 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837 |
0.5 µM [IC50] | ||
Target ID: CHEMBL1874 Sources: http://www.drugbank.ca/drugs/DB00214 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date1993 |
|||
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date1993 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
968.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1549.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1561 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3516 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TORSEMIDE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.124 |
unhealthy Health Status: unhealthy Condition: Chronic renal failure Sources: Page: p.124 |
|
800 mg single, intravenous Highest studied dose Dose: 800 mg Route: intravenous Route: single Dose: 800 mg Sources: Page: p.124, 133 |
unhealthy Health Status: unhealthy Condition: Acute renal failure Sources: Page: p.124, 133 |
|
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Disc. AE: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Dizziness (0.1 - 0.5) Sources: Page: p.11Headache (0.1 - 0.5) Nausea (0.1 - 0.5) Weakness (0.1 - 0.5) Vomiting (0.1 - 0.5) Hyperglycemia (0.1 - 0.5) Urination abnormal NOS (0.1 - 0.5) Hyperuricemia (0.1 - 0.5) Hypokalemia (0.1 - 0.5) Excessive thirst (0.1 - 0.5) Hypovolemia (0.1 - 0.5) Impotence (0.1 - 0.5) Esophageal hemorrhage (0.1 - 0.5) Dyspepsia (0.1 - 0.5) |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Disc. AE: Electrolyte depletion, Electrolyte depletion... Other AEs: Hepatic coma, Tinnitus... AEs leading to discontinuation/dose reduction: Electrolyte depletion Other AEs:Electrolyte depletion Hypokalemia Hepatic coma Sources: Page: p.6Tinnitus Hearing loss |
200 mg 1 times / day multiple, intravenous Studied dose Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 44 Health Status: unhealthy Condition: Advanced chronic renal failure Population Size: 44 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Dyspepsia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Esophageal hemorrhage | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Excessive thirst | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Headache | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperglycemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperuricemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypokalemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypovolemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Impotence | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Nausea | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Urination abnormal NOS | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Vomiting | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Weakness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hearing loss | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Hepatic coma | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Tinnitus | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Hypokalemia | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 9.0 |
minor | |||
Page: 9.0 |
minor | |||
Page: 5.0 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats. | 2001 |
|
[Torasemide (LUPRAC): a review of its pharmacological and clinical profile]. | 2001 Aug |
|
Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. | 2001 Summer |
|
Torasemide in chronic heart failure: results of the TORIC study. | 2002 Aug |
|
[A better diuretic for patients with heart failure. Better control of potassium loss]. | 2002 Aug 8 |
|
Diuretics in the therapy of hypertension. | 2002 Mar |
|
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. | 2003 |
|
[Torasemide (Trifas) in clinical practice--own experience]. | 2003 |
|
A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. | 2003 Aug |
|
Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. | 2003 Dec |
|
[Favorable prognostic effect of heart failure therapy. Diuretic makes heart muscle more elastic]. | 2003 Jun 5 |
|
Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. | 2003 Nov |
|
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). | 2004 Feb 23 |
|
Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. | 2004 Jan |
|
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. | 2004 Jun 2 |
|
Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. | 2004 Jun 22 |
|
[Idiopathic hypereosinophilia with cardiac involvement]. | 2004 Mar 12 |
|
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. | 2004 May |
|
A woman with infectious endocarditis caused by Abiotrophia defectiva. | 2004 Oct |
|
[The place of diuretics in the treatment of chronic heart failure. Part I]. | 2005 |
|
Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. | 2005 |
|
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | 2005 Aug |
|
[Aldosterone antagonist therapy for chronic heart failure]. | 2005 Feb 10 |
|
Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Electrochemical characterisation of the human cytochrome P450 CYP2C9. | 2005 May 15 |
|
Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. | 2005 Nov |
|
Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. | 2005 Spring |
|
[Torasemide--new generation loop diuretic: clinical pharmacology and therapeutic application]. | 2006 |
|
Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. | 2006 Feb 2 |
|
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. | 2006 Jul 17 |
|
Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs. | 2006 Nov |
|
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. | 2006 Nov 15 |
|
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. | 2006 Oct |
|
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. | 2007 Apr |
|
Torasemide transport by organic anion transporters contributes to hyperuricemia. | 2007 Dec |
|
Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. | 2007 Feb |
Patents
Sample Use Guides
Congestive Heart Failure
The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex (Torasemide). If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied.
Chronic Renal Failure
The usual initial dose of Demadex is 20 mg of once-daily oral Demadex.
Hypertension
The usual initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be increased to 10 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837
Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 umol/L) in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats..
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:48 GMT 2023
by
admin
on
Fri Dec 15 15:31:48 GMT 2023
|
Record UNII |
W31X2H97FB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC03CA04
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
LIVERTOX |
984
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
WHO-ATC |
C03CA04
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NDF-RT |
N0000175366
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NCI_THESAURUS |
C49184
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
UPCARD [AUTHORIZED]
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NDF-RT |
N0000175590
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1672304
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
TORASEMIDE
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
C29506
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
DB00214
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
W31X2H97FB
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
56211-40-6
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
2708
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1148
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
SUB11195MIG
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
C026116
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
7312
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
9637
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
38413
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
3938
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
DTXSID2023690
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
100000090291
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
41781
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
m10981
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
Torsemide
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
W31X2H97FB
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
POTENCY
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity A = 5.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|